Main Article Content
Hot flushes or hot flashes are one of the vasomotor symptoms frequently found in menopausal women and andropausal men. Pine pollen has been used in traditional Chinese medicine (TCM) for health restoration, anti-aging, and longevity tonic supplements. Since Scotch pine contains steroid hormones, it has been claimed for maintaining men’s health. This study aimed to investigate the effects of pine pollen extract from Pinus patula ssp. tecunumanii in relieving hot flushes in rats with sex hormone depletion. Alpha-calcitonin gene-related peptide (αCGRP) was injected into female rats every other day for tail skin temperature (TST) elevation. Pine pollen extract significantly reduced TST in a concentration-dependent manner on the 3rd day of oral administration. Conjugated equine estrogen (CEE), used for estrogen replacement therapy, spent more time to reduce TST than pine pollen extract did (the 6th day of administration), and continuously decreased TST until the end of experiment. While TST in male rats was increased by daily injection of leuprorelin acetate, the pine pollen extract significantly reduced TST in a dose dependent manner on the 2nd day of oral administration. Testosterone undecanoate (TU), used for hormone replacement therapy in men, significantly reduced TST on every days of oral administration. The ELISA results showed that uterine estrogen concentrations of CEE and pine pollen extract treated groups were significantly higher than control while no significant difference in serum estrogen levels was found. Only serum testosterone concentration of TU treated group was significantly higher than control while testis weights of all groups were lower than sham-treated group. Pine pollen extract from Pinus patula ssp. tecunumanii could be classified as a phyto-androgen that might balance testosterone and estrogen levels, resulting in alleviating the symptoms of sex hormone deficiency such as hot flushes, night sweating, and sleep disturbance.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Upon acceptance of an article, the Pharmacological and Therapeutic Society of Thailand will have exclusive right to publish and distribute the article in all forms and media and grant rights to others. Authors have rights to use and share their own published articles.
2. Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011;117(5):1095-104.
3. สุรศักดิ์ อังสุวัฒนา. วัยหมดประจำเดือน (ตอนที่ 1). [อินเทอร์เน็ต]. 2553 [เข้าถึงเมื่อ 11 มกราคม 2560]. เข้าถึงได้จาก: http://www.si.mahidol.ac.th/sidoctor/e-pl/articledetail. asp?id=166
4. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocr Metab. 2001;86(2):724-31.
5. Karling P, Hammer M, and Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol. 1994;152:1170-3.
6. Reed SD, Ludman EJ, Newton KM, Grothaus LC, LaCroix AZ, Nekhlyudov L, et al. Depressive symptoms and menopausal burden in the midlife. Maturitas. 2009;62:306–10.
7. Stahl SM. Vasomotor symptoms and depression in women, part I. Role of vasomotor symptoms in signaling the onset or relapse of a major depressive episode. J Clin Psychiatry. 2009;70:11–2.
8. Jan LS. Menopause. In: Berek JS, editor. Berek & Novak's gynecology. 14th ed. Philadelphia: Lippincott William & Wilkins; 2007.
9. ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-16.
10. North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause. 2012; 19(3):257-71.
11. de Villiers TJ, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD, et al. Global consensus statement on menopausal hormone therapy. Climacteric. 2013;16(2):203-4.
12. Stampfer MJ, Colditz, GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20(1):47–63.
13. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75(6):1102–9.
14. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117(12):1016–37.
15. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med. 1991;151(1):67–72.
16. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265(15):1985–90.
17. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350(9084):1047–59.
18. Laakmann E, Grajecki D, Doege K, zu Eulenburg C, Buhling KJ. Efficacy of Cimicifuga racemosa, Hypericum perforatum and Agnus castus in the treatment of climacteric complaints: a systematic review. Gynecol Endocrinol. 2012;28:703-9.
19. Johns C, Seav SM, Dominick SA, Gorman JR, Li H, Natarajan L, et al. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Res Treat. 2016;156:415-26.
20. Rada G, Capurro D, Pantoja T, Corbalán J, Moreno G, Letelier LM, Vera C. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev. 2011; CD004923.
21. Haque R, Shi J, Schottinger JE, Ahmed SA, Cheetham TC, Chung J, et al. Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst 2016; 108(3).
22. Joffe H, Guthrie, KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med. 2014;174:1058-66.
23. Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2011;29:3862-8.
24. Grunert J. Advantages and disadvantages of herbal medicines. [Internet] 2017. Available from: http://www.herbs.lovetoknow.com/Advantages_and_ Disadvantages_of_Herbal_Medicines
25. Raw forest foods. Historical and Chinese medicine perspective of pine pollen. [Internet] 2017. Available from: http://www.rawforestfoods.com/historical-and-chinese-medicine-perspective-of-pine-pollen/
26. Saden-Krehula M, Tajic M, Kolbah D. Testosterone, epitestosterone, androstenedione in the pollen of scotch pine P. silvestris L. Experientia. 1971; 27:108-9.
27. สำนักวิจัยการจัดการป่าไม้และผลิตผลป่าไม้ กรมป่าไม้. การปรับปรุงพันธุ์ไม้สนในประเทศไทย. ครั้งที่ 1. กรุงเทพฯ: โรงพิมพ์ชุมนุมสหกรณ์การเกษตรแห่งประเทศไทย จำกัด; 2551.
28. Yan L. Notification of Statement of Nutritional Support on Dietary Supplement Chinese Pine Pollen [letter]. 1998.
29. Part 5: Preparation, reading and reporting of vaginal smears. [Internet] Available from: http://www.oecd.org/chemicalsafety/testing/40581357.pdf
30. Chamawan P, Thisayakorn K, Phornchirasilp S. Comparative study on hot flushes model in both sexes of rats: a preliminary study. In: Conference Proceeding; The 13th Asia Pacific Federation of Pharmacologist (APFP) Meeting; 2016 Feb 1-3; The Berkeley Hotel, Pratunum, Bangkok: Thailand. 2016. p. 14-20.
31. Fritz MA, Speroff L. Clinical Gynecologic Endocrinology and Infertility. 2012. Lippincott Williams & Wilkins. pp. 751.
32. Troy SM, Hicks DR, Parker VD, Jusko WJ, Rofsky HE, Porter RJ. Differences in pharmacokinetics and comparative bioavailability between premarin® and estratab® in healthy postmenopausal women. CTR 1994;55:359-72.
33. Muchow M, Maincent P, Müller RH, and Keck CM. Testosterone undecanoate - increase of oral bioavailability by nanostructured lipid carriers (NLC). JPTDR 2013;1-10.
34. de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol. 2011;9:93.
35. Ishikawa T, Glidewell-Kenney C, Jameson JL. Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5α-reductase inhibitor. J Steroid Biochem Mol Biol. 2006;98(2-3):133-8.